Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 6
2013 10
2014 3
2016 3
2017 2
2018 6
2019 1
2020 2
2021 3
2022 4
2023 3
2024 1
2025 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation.
Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. Chang L, et al. Gastroenterology. 2022 Jul;163(1):118-136. doi: 10.1053/j.gastro.2022.04.016. Gastroenterology. 2022. PMID: 35738724
The technical review panel prioritized clinical questions and outcomes according to their importance for clinicians and patients and conducted an evidence review of the following agents: tenapanor, plecanatide, linaclotide, tegaserod, lubiprostone, polyethylene glyc …
The technical review panel prioritized clinical questions and outcomes according to their importance for clinicians and patients and …
Bowel preparation efficacy and safety of compound polyethylene glycol electrolyte powder combined with linaclotide for colonoscopy: A randomized controlled trial.
Yang J, Wei Q, Xiang Z, Wu D, Lin Z. Yang J, et al. JGH Open. 2023 Aug 31;7(9):636-639. doi: 10.1002/jgh3.12961. eCollection 2023 Sep. JGH Open. 2023. PMID: 37744708 Free PMC article.
BACKGROUND AND AIM: Adequate bowel preparation is essential for colonoscopy, which is important for detecting colon polyps and preventing colorectal cancer. Linaclotide is approved for irritable bowel syndrome with predominant constipation (IBS-C) symptoms. T …
BACKGROUND AND AIM: Adequate bowel preparation is essential for colonoscopy, which is important for detecting colon polyps and preventing co …
Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub-cohort analysis of a phase III, randomized, double-blind, placebo-controlled trial.
Peng LH, Fang JY, Dai N, Shen XZ, Yang YL, Sun J, Yang YS. Peng LH, et al. J Dig Dis. 2022 Feb;23(2):99-110. doi: 10.1111/1751-2980.13081. J Dig Dis. 2022. PMID: 35019221 Free PMC article. Clinical Trial.
OBJECTIVE: To conduct a sub-cohort analysis to evaluate the efficacy and safety of linaclotide in Chinese patients with constipation-predominant irritable bowel syndrome (IBS-C) using data from a completed trial (NCT01880424). METHODS: In this phase II …
OBJECTIVE: To conduct a sub-cohort analysis to evaluate the efficacy and safety of linaclotide in Chinese patients with constipation- …
Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis.
Atluri DK, Chandar AK, Bharucha AE, Falck-Ytter Y. Atluri DK, et al. Neurogastroenterol Motil. 2014 Apr;26(4):499-509. doi: 10.1111/nmo.12292. Epub 2013 Dec 18. Neurogastroenterol Motil. 2014. PMID: 24351035
BACKGROUND: Treatment options for constipation-predominant irritable bowel syndrome (IBS-C) are limited. While linaclotide improved IBS-C symptoms in randomized controlled trials (RCTs), results vary among studies and the magnitude …
BACKGROUND: Treatment options for constipation-predominant irritable bowel syndrome (IBS-C) are limited. While linaclotide …
Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
Quigley EM, Tack J, Chey WD, Rao SS, Fortea J, Falques M, Diaz C, Shiff SJ, Currie MG, Johnston JM. Quigley EM, et al. Aliment Pharmacol Ther. 2013 Jan;37(1):49-61. doi: 10.1111/apt.12123. Epub 2012 Nov 1. Aliment Pharmacol Ther. 2013. PMID: 23116208 Free article. Clinical Trial.
BACKGROUND: Treatment options that improve overall symptoms of irritable bowel syndrome with constipation (IBS-C) are lacking. AIM: A prespecified further analysis to evaluate the efficacy and safety of linaclotide, a guanylate cyclase C agonist, in patients …
BACKGROUND: Treatment options that improve overall symptoms of irritable bowel syndrome with constipation (IBS-C) are lacking. …
Safety and efficacy of linaclotide in children aged 7-17 years with irritable bowel syndrome with constipation.
Di Lorenzo C, Nurko S, Hyams JS, Rodriguez-Araujo G, Shakhnovich V, Saps M, Simon M. Di Lorenzo C, et al. J Pediatr Gastroenterol Nutr. 2024 Mar;78(3):539-547. doi: 10.1002/jpn3.12103. Epub 2023 Dec 28. J Pediatr Gastroenterol Nutr. 2024. PMID: 38504394 Clinical Trial.
This study evaluated the safety and efficacy of various linaclotide doses in children 7-17 years old with irritable bowel syndrome with constipation (IBS-C). METHODS: In this 4-week, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 …
This study evaluated the safety and efficacy of various linaclotide doses in children 7-17 years old with irritable bowel syndrome wi …
Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
Yang Y, Fang J, Guo X, Dai N, Shen X, Yang Y, Sun J, Bhandari BR, Reasner DS, Cronin JA, Currie MG, Johnston JM, Zeng P, Montreewasuwat N, Chen GZ, Lim S. Yang Y, et al. J Gastroenterol Hepatol. 2018 May;33(5):980-989. doi: 10.1111/jgh.14086. Epub 2018 Mar 12. J Gastroenterol Hepatol. 2018. PMID: 29319191 Clinical Trial.
China has unmet need for well-tolerated therapy that is effective in treating both bowel and abdominal symptoms of IBS-C. This trial evaluated linaclotide's efficacy and safety in IBS-C patients in China and other regions. METHODS: This P …
China has unmet need for well-tolerated therapy that is effective in treating both bowel and abdominal symptoms of IBS-C. This …
Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation.
Nelson AD, Black CJ, Houghton LA, Lugo-Fagundo NS, Lacy BE, Ford AC. Nelson AD, et al. Aliment Pharmacol Ther. 2021 Jul;54(2):98-108. doi: 10.1111/apt.16437. Epub 2021 Jun 11. Aliment Pharmacol Ther. 2021. PMID: 34114657 Free article.
METHODS: We searched the medical literature through December 2020 to identify randomised controlled trials (RCTs) in IBS-C, with abdominal bloating reported as a dichotomous assessment. ...CONCLUSIONS: We found all licensed drugs for IBS-C …
METHODS: We searched the medical literature through December 2020 to identify randomised controlled trials (RCTs) in IBS …
A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K, MacDougall JE, Shao JZ, Eng P, Fox SM, Schneier HA, Kurtz CB, Johnston JM. Rao S, et al. Am J Gastroenterol. 2012 Nov;107(11):1714-24; quiz p.1725. doi: 10.1038/ajg.2012.255. Am J Gastroenterol. 2012. PMID: 22986440 Free PMC article. Clinical Trial.
OBJECTIVES: Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C). METHODS: This p …
OBJECTIVES: Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the …
42 results